More stem cells. More transplant success.

ViaCord has the highest published transplant success rates.[2,9a]

FOR CURRENT TREATMENTS*- *All transplant recipients were conditioned with chemotherapy/radiation prior to treatment*

Diagnosis	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Thalassemia	07/16	4	9	Sibling	6.81
Juvenile myelomonocytic leukemia (JMML)	05/16	2	1	Sibling	2.65
Severe Congenital Neutropenia	02/16	16	39	Sibling	5.85
Diamond Blackfan Anemia	11/15	4	28	Sibling	10.88
Sickle Cell Disease	11/15	12	13	Sibling	8.60
Thalassemia	10/15	6	15	Sibling	7.08
Severe Congenital Neutropenia	08/15	4	14	Sibling	6.07
Sickle Cell Disease	07/15	14	45	Sibling	8.33
Sickle Cell Disease	05/15	4	14	Sibling	6.36
Diamond Blackfan Anemia	04/15	5	17	Sibling	10.43
Thalassemia	04/15	5	12	Sibling	7.05
Acute Lymphoblastic Leukemia	04/15	9	23	Sibling	5.95
Sickle Cell Disease	04/15	8	32	Sibling	4.24
Acute Myelogenous Leukemia	04/15	2	21	Self	8.86
Acute Lymphoblastic Leukemia	04/15	6	45	Sibling	6.46
Acute Lymphoblastic Leukemia	01/15	4	1	Sibling	5.68
Sickle Cell Disease	08/14	8	86	Sibling	5.20
Sickle Cell Disease	08/14	8	86	Sibling	12.48
Acute Myelogenous Leukemia	05/14	4	11	Sibling	6.58
SCIDS-Adenosine Deaminase Deficiency	04/14	1	4	Sibling	6.08
Sickle Cell Disease	04/14	11	87	Sibling	2.97
Sickle Cell Disease	04/14	3	7	Sibling	8.63
Leukemia	03/14	3	21	Sibling	7.96
Sickle Cell Disease	02/14	3	20	Sibling	8.14
Chronic Myelogenous Leukemia	01/14	6	9	Sibling	6.16
Sickle Cell Disease	08/13	9	56	Sibling	5.69
Sickle Cell Disease	07/13	11	29	Sibling	6.46
Thalassemia Major	06/13	8	16	Sibling	13.40
Fanconi Anemia	05/13	9	3	Sibling	5.49
Chronic Granulomatous Disease	03/13	9	13	Sibling	4.83
Wiskott-Aldrich Syndrome	02/13	4	18	Sibling	6.56

CHILDREN'S HOSPITAL & RESEARCH CENTER OAKLAND

www.viacord.com | 866-835-0968

VIACORD®
From PerkinElmer

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FOR CURRENT TREATMENTS*- *All transplant recipients were conditioned with chemotherapy/radiation prior to treatment*

Diagnosis	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Diamond Blackfan Anemia	02/13	4	20	Sibling	3.85
Juvenile Myelomonocytic Leukemia	01/13	4	2	Sibling	10.66
Beta Thalassemia Major	09/12	3	13	Sibling	2.81
Acute Myelogenous Leukemia	07/12	3	4	Sibling	7.06
Diamond-Blackfan Anemia	06/12	6	16	Sibling	12.95
Beta Thalassemia	4/12	6	33	Sibling	15.65
Sickle Cell Disease	03/12	3	15	Sibling	20.10
Sickle Cell Disease	03/12	8	24	Sibling	1.68
Sickle Cell Disease	03/12	12	101	Sibling	22.24
Aplastic Anemia	02/12	12	19	Sibling	5.64
Acute Myelogenous Leukemia	02/12	3	8	Sibling	5.23
Fanconi Anemia	01/12	6	7	Sibling	4.83
Fanconi Anemia	01/12	6	11	Sibling	6.27
Thalassemia Major	08/11	8	15	Sibling	4.32
E Beta Thalassemia	07/11	14	22	Sibling	11.78
E Beta Thalassemia	05/11	7	26	Sibling	6.19
Acute Myeloid Leukemia	05/11	2	2	Sibling	2.86
Sickle Cell Disease	03/11	8	15	Sibling	4.32
Sickle Cell Disease	03/11	10	18	Sibling	9.34
Acute Lymphoblastic Leukemia	03/11	7	27	Sibling	8.57
Sickle Cell Disease	02/11	7	26	Sibling	6.40
Sickle Cell Disease	09/10	5	9	Sibling	7.50
Sickle Cell Disease	09/10	4	9	Sibling	2.92
Aplastic Anemia	09/10	4	49	Sibling	12.17
Acute Myelogenous Leukemia	09/10	4	15	Sibling	11.05
Acute Lymphoblastic Leukemia	08/10	4	5	Sibling	6.53
Sickle Cell Disease	07/10	6	24	Sibling	9.84
Cartilage-Hair Hypoplasia	07/10	2	10	Sibling	11.58
Myelodysplastic Syndrome	05/10	4	42	Self	5.57
Thalassemia Major	03/10	6	9	Sibling	15.55
Acute Lymphoblastic Leukemia	12/09	5	4	Sibling	3.63
Sickle Cell Disease	11/09	10	47	Sibling	9.60
Acute Myleoid Leukemia	10/09	2	4	Sibling	12.73
Acute Lymphoblastic Leukemia	08/09	3	3	Sibling	13.08
Sickle Cell Disease	07/09	9	11	Sibling	2.88
Sickle Cell Disease	07/09	6	6	Sibling	8.76
Chronic Granulomatous Disease	07/09	5	12	Sibling	8.65
Sickle Cell Disease	06/09	6	46	Sibling	30.94
Sickle Cell Disease	06/09	6	6	Sibling	5.92
Sickle Cell Disease	04/09	8	43	Sibling	13.65
Fanconi Anemia	04/09	5	19	Sibling	7.28
Severe Aplastic Anemia	01/09	5	54	Self	6.81
Primitive Neuronal Tumor	12/08	9 months	9	Self	4.92
Non-Hodgkin's Lymphoma	12/08	7	42	Sibling	7.75
Acute Lymphoblastic Leukemia	12/08	10	4	Sibling	9.55

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FOR CURRENT TREATMENTS*- *All transplant recipients were conditioned with chemotherapy/radiation prior to treatment*

Diagnosis	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Sickle Cell Disease	08/08	9	91	Sibling	9.56
Acute Lymphoblastic Leukemia	08/08	6	23	Sibling	12.80
Sickle Cell Disease	07/08	2	7	Sibling	3.82
Acute Myelogenous Leukemia	07/08	2	2	Sibling	3.80
Thalassemia Major	05/08	2	96	Sibling	30.00
Thalassemia Major	05/08	5	7	Sibling	14.04
Acute Lymphoblastic Leukemia	01/08	3	9	Sibling	11.70
Thalassemia Major	12/07	9	14	Sibling	10.18
Sickle Cell Disease	10/07	10	29	Sibling	10.65
Fanconi Anemia	10/07	3	9	Sibling	7.64
Sickle Cell Disease	09/07	3	14	Sibling	8.93
Sickle Cell Disease	09/07	1	2	Sibling	14.66
Severe Combined Immunodeficiency	06/07	6	8	Sibling	6.70
Severe Aplastic Anemia	06/07	4	4	Sibling	15.20
Chronic Granulomatous Disease	06/07	5	9	Sibling	7.35
Acute Lymphoblastic Leukemia	06/07	6	3	Sibling	12.32
Acute Lymphoblastic Leukemia	05/07	6	39	Sibling	16.56
Sickle Cell Disease	04/07	10	24	Sibling	7.42
Acute Lymphoblastic Leukemia	04/07	7	22	Sibling	4.37
Brain Cancer	03/07	11 months	11	Self	2.65
Acute Lymphoblastic Leukemia	03/07	7	39	Sibling	16.70
Thalassemia Major	02/07	3	13	Sibling	11.22
Severe Congenital Neutropenia	02/07	4	29	Sibling	3.08
Sickle Cell Disease	01/07	7	21	Sibling	7.77
Sickle Cell Disease	01/07	14	22	Sibling	7.30
Acute Myelogenous Leukemia	01/07	8	38	Sibling	2.77
Acute Myelogenous Leukemia	12/06	3	3	Sibling	6.58
Acute Myelogenous Leukemia	10/06	3	1	Sibling	7.70
Sickle Cell Disease	09/06	5	24	Sibling	11.74
Thalassemia Major	08/06	6	18	Sibling	14.77
Sickle Cell Disease	06/06	11	15	Sibling	11.66
Sickle Cell Disease	05/06	8	55	Sibling	9.80
Shwachman-Diamond Anemia	05/06	7	13	Sibling	5.61
Acute Lymphoblastic Leukemia	05/06	13	50	Sibling	12.66
Lymphoma	04/06	3	35	Sibling	22.45
Thalassemia Major	03/06	6	23	Sibling	8.42
Myelodysplastic Syndrome	03/06	5	7	Sibling	9.09
Acute Lymphoblastic Leukemia	01/06	5	2	Sibling	16.66
Severe Aplastic Leukemia	12/05	7	10	Sibling	7.70
Sickle Cell Disease	10/05	12	57	Sibling	18.80
Adrenoleukodystrophy	10/05	4	39	Sibling	6.96
Thalassemia Major	09/05	5	8	Sibling	26.80
Sickle Cell Disease	09/05	11	12	Sibling	3.42
Sickle Cell Disease	07/05	8	13	Sibling	9.48
Beta Thalassemia Intermedia	07/05	9	14	Sibling	5.02

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FOR CURRENT TREATMENTS*- *All transplant recipients were conditioned with chemotherapy/radiation prior to treatment*

Diagnosis	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Acute Lymphoblastic Leukemia	06/05	3	8	Sibling	15.32
Acute Myelogenous Leukemia	05/05	3	2	Sibling	9.28
Thalassemia Major	03/05	5	13	Sibling	18.10
Kostmann Syndrome	03/05	3	8	Sibling	5.95
Acute Myelogenous Leukemia	03/05	4	28	Sibling	6.86
Thalassemia Major	01/05	4	8	Sibling	15.14
Thalassemia Major	01/05	4	22	Sibling	7.30
Fanconi Anemia	01/05	8	7	Sibling	3.15
Thalassemia Major	12/04	6	16	Sibling	8.22
Thalassemia Major	12/04	5	25	Sibling	9.64
Thalassemia Major	11/04	15	37	Sibling	8.30
Ectodermal Dysplasia	10/04	5	7	Sibling	9.65
Thalassemia Major	09/04	9	6	Sibling	13.32
Thalassemia Major	08/04	8	26	Sibling	5.10
Acute Myelogenous Leukemia	02/04	2	4	Sibling	10.81
Sickle Cell Disease	01/04	2	7	Sibling	3.04
Thalassemia Major	12/03	5	9	Sibling	8.25
Acute Lymphoblastic Leukemia	12/03	3	12	Sibling	16.58
Hurler Syndrome	11/03	2	5	Sibling	2.76
Wiskott-Aldrich Syndrome	10/03	2	2	Sibling	9.08
Acute Lymphoblastic Leukemia	09/03	8	17	Sibling	9.85
Fanconi Anemia	08/03	5	80	Sibling	6.90
Diamond-Blackfan Anemia	08/03	7	14	Sibling	6.93
Acute Lymphoblastic Leukemia	08/03	6	44	Sibling	4.00
Sickle Cell Disease	06/03	9	8	Sibling	16.50
Acute Lymphoblastic Leukemia	06/03	3	21	Sibling	6.20
Thalassemia Major	05/03	7	8	Sibling	5.83
Severe Aplastic Anemia	05/03	2	3	Sibling	10.51
Acute Lymphoblastic Leukemia	05/03	3	2	Sibling	22.32
Acute Myelogenous Leukemia	03/03	5	2	Sibling	17.41
Myelodysplastic Syndrome	01/03	6	8	Sibling	12.82
Acute Lymphoblastic Leukemia	01/03	7	29	Sibling	13.10
Acute Myelogenous Leukemia	12/02	2	3	Sibling	7.42
Acute Lymphoblastic Leukemia	11/02	4	4	Sibling	15.39
Sickle Cell Disease	10/02	5	18	Sibling	7.00
Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked Syndrome	09/02	2	6	Sibling	7.63
Acute Myelogenous Leukemia	08/02	4	22	Sibling	4.40
Sickle Cell Disease	07/02	6	13	Sibling	5.40
Acute Myelogenous Leukemia	07/02	4	3	Sibling	11.54
Acute Myelogenous Leukemia	06/02	2	1	Sibling	25.14
Fanconi Anemia	04/02	3	16	Sibling	1.10
Chronic Granulomatous Disease	04/02	6	13	Sibling	7.20
Thalassemia Major	02/02	2	13	Sibling	17.80
Acute Lymphoblastic Leukemia	01/02	5	5	Sibling	5.00

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FOR CURRENT TREATMENTS*- *All transplant recipients were conditioned with chemotherapy/radiation prior to treatment*

Diagnosis	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Sickle Cell Disease	12/01	14	32	Sibling	9.00
Neuroblastoma	12/01	6	67	Self	4.10
Thalassemia Major	11/01	7	8	Sibling	6.90
Sickle Cell Disease	11/01	7	20	Sibling	7.80
Acute Lymphoblastic Leukemia	07/01	6	17	Sibling	9.40
Severe Aplastic Anemia	06/01	10	39	Sibling	10.80
Severe Aplastic Anemia	04/01	2	20	Self	14.10
Thalassemia Major	12/00	4	23	Sibling	6.20
Thalassemia Major	12/00	3	11	Sibling	5.00
Acute Myelogenous Leukemia	11/00	3	4	Sibling	10.70
Thalassemia Major	10/00	4	13	Sibling	13.00
Severe Aplastic Anemia	10/00	13	13	Sibling	7.32
Sickle Cell Disease	07/00	4	25	Sibling	4.00
Thalassemia Major	06/00	4	16	Sibling	11.00
Sickle Cell Disease	05/00	10	8	Sibling	15.00
Sickle Cell Disease	02/00	8	23	Sibling	10.60
Sickle Cell Disease	09/99	2	9	Sibling	10.80
SCID/Myelodysplastic Syndrome	09/99	7	7	Sibling	18.00
Fanconi Anemia	06/99	4	6	Sibling	15.10
Thalassemia Major	12/98	2	7	Sibling	9.00
Thalassemia Major	06/98	4	6	Sibling	8.40
Acute Myelogenous Leukemia	12/97	4	<1	Sibling	7.10
Wiskott-Aldrich Syndrome	11/97	3	4	Sibling	14.20
Severe Aplastic Anemia	09/97	3	9	Sibling	1.27
Acute Lymphoblastic Leukemia	06/96	8	2	Sibling	7.40

FOR EMERGING RESEARCH***- *The diseases listed below are being studied subject to FDA-approved Clinical Trials*

Diagnosis Studied	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Autism Spectrum Disorder	06/16	<1	11	Self	6.40
Cerebral Palsy	03/16	1	60	Sibling	6.28
Apraxia	03/16	5	69	Self	10.20
Cerebral Palsy	03/16	4	7	Sibling	9.26
Cerebral Palsy	03/16	2	4	Sibling	7.24
Cerebral Palsy	03/16	5	42	Sibling	8.47
Apraxia	03/16	4	56	Self	13.38
Apraxia	02/16	8	98	Self	2.29
Apraxia	01/16	7	95	Self	3.75
Cerebral Palsy	12/15	3	9	Sibling	8.92
Cerebral Palsy	09/15	<1	9	Self	4.45
Obstructive Hydrocephalus, Nystgamus and Cerebral Palsy	0815	<1	10	Self	5.59
Cerebral Palsy	07/15	4	52	Self	5.59
Cerebral Palsy	01/15	5	51	Self	11.03
Cerebral Palsy	01/15	1	10	Self	8.40

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FOR EMERGING RESEARCH*** - *The diseases listed below are being studied subject to FDA-approved Clinical Trials*

Diagnosis Studied	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Autism Spectrum Disorder	12/14	4	42	Self	4.73
Autism Spectrum Disorder	12/14	6	61	Self	8.57
Autism Spectrum Disorder	11/14	5	65	Self	2.76
Autism Spectrum Disorder	11/14	5	65	Self	12.09
Autism Spectrum Disorder	11/14	4	56	Self	17.68
Autism Spectrum Disorder	11/14	3	35	Self	3.87
Autism Spectrum Disorder	10/14	5	64	Self	4.50
Cerebral Palsy	10/14	10	124	Self	7.87
Autism Spectrum Disorder	10/14	5	61	Self	20.77
Cerebral Palsy	10/14	5	58	Self	3.75
Autism Spectrum Disorder	09/14	6	67	Self	5.30
Cerebral Palsy	09/14	2	27	Self	1.73
Autism Spectrum Disorder	08/14	5	55	Self	7.06
Autism Spectrum Disorder	07/14	3	33	Self	7.63
Autism Spectrum Disorder	07/14	6	69	Self	9.72
Cerebral Palsy	04/14	2	21	Self	7.63
Hydrocephalus/Brain Injury	04/14	3	31	Self	7.63
Stroke Injury	12/13	6	76	Self	3.93
Cerebral Palsy	09/13	7 months	8	Self	4.50
Cerebral Palsy	07/13	4	48	Self	5.18
Cerebral Palsy	05/13	5	60	Self	4.97
Cerebral Palsy	03/13	1	12	Self	21.32
Hydrocephalus	03/13	4 months	4	Self	6.86
Cerebral Palsy	02/13	3	34	Self	4.18
Cerebral Palsy	01/13	3	30	Self	1.63
Cerebral Palsy	01/13	4	53	Self	7.60
Septic Brain Injury	11/12	7 months	7	Self	7.42
Cerebral Palsy	11/12	7	83	Self	4.88
Cerebral Palsy	10/12	1	16	Self	7.83
Cerebral Palsy	07/12	3	34	Self	7.70
Cerebral Palsy	06/12	2	23	Self	5.10
Cerebral Palsy	06/12	6	73	Self	19.35
Cerebral Palsy	04/12	2	22	Self	3.22
Cerebral Palsy	04/12	1	17	Self	8.09
Cerebral Palsy	03/12	2	21	Self	1.78
Cerebral Palsy	03/12	3	35	Self	8.24
Cerebral Palsy	02/12	1	11	Self	1.22
Cerebral Palsy	01/12	4	51	Self	3.04
Cerebral Palsy	12/11	1	16	Self	4.32
Hemophagocytic Lymphohistiocytosis	11/11	9	105	Self	5.40
Cerebral Palsy	11/11	4	43	Self	14.16
Cerebral Palsy	09/11	4	44	Self	5.24
Hydrocephalus	09/11	3 months	3	Self	5.83
Cerebral Palsy	09/11	3	35	Self	7.12
Cerebral Palsy	09/11	3	34	Self	6.48

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FOR EMERGING RESEARCH*** - *The diseases listed below are being studied subject to FDA-approved Clinical Trials*

Diagnosis Studied	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Cerebral Palsy	08/11	3	30	Self	3.10
Cerebral Palsy	08/11	5	58	Self	7.75
Cerebral Palsy	07/11	5	54	Self	1.20
Cerebral Palsy	05/11	1	8	Self	3.13
Cerebral Palsy	04/11	6	73	Self	4.04
Cerebral Palsy	04/11	3	37	Self	7.37
Cerebral Palsy	04/11	1	10	Self	2.00
Cerebral Palsy	01/11	1	16	Self	9.82
Cerebral Palsy	01/11	2	27	Self	11.60
Cerebral Palsy	01/11	2	25	Self	2.93
Type 1 Diabetes	12/10	10	116	Self	6.00
Cerebral Palsy	12/10	4	52	Self	5.00
Cerebral Palsy	11/10	2	25	Self	6.50
Cerebral Palsy	11/10	4	48	Self	2.46
Cerebral Palsy	11/10	2 months	2	Self	1.90
Cerebral Palsy	11/10	1	14	Self	1.91
Cerebral Palsy	10/10	5	61	Self	8.23
Cerebral Palsy	08/10	8	100	Self	10.50
Cerebral Palsy	07/10	1	13	Self	5.20
Cerebral Palsy	06/10	2	27	Self	2.09
Cerebral Palsy	06/10	7 months	7	Self	7.41
Hydrocephalus	05/10	2 months	2	Self	1.93
Cerebral Palsy	02/10	1	13	Self	8.98
Cerebral Palsy	01/10	8	95	Self	6.40
Cerebral Palsy	01/10	3	40	Self	10.14
Cerebral Palsy	01/10	4	46	Self	13.78
Type 1 Diabetes	12/09	7	83	Self	3.70
Cerebral Palsy	12/09	2	27	Self	1.98
Cerebral Palsy	11/09	3	35	Self	8.35
Cerebral Palsy	11/09	3	39	Self	3.20
Cerebral Palsy	11/09	5	53	Self	6.44
Cerebral Palsy	10/09	1	17	Self	4.96
Cerebral Palsy	10/09	4	50	Self	2.66
Type 1 Diabetes	09/09	7	77	Self	6.60
Cerebral Palsy	09/09	3	31	Self	11.88
Cerebral Palsy	09/09	4	48	Self	17.23
Cerebral Palsy	09/09	4	42	Self	10.78
Cerebral Palsy	09/09	3	32	Self	7.49
Cerebral Palsy	09/09	3	31	Self	2.76
Cerebral Palsy	07/09	4	44	Self	5.40
Cerebral Palsy	07/09	2	24	Self	3.23
Cerebral Palsy	07/09	5	57	Self	12.84
Cerebral Palsy	06/09	3	32	Self	16.64
Cerebral Palsy	06/09	3	31	Self	1.80
Cerebral Palsy	06/09	2	21	Self	5.90

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FOR EMERGING RESEARCH*** - *The diseases listed below are being studied subject to FDA-approved Clinical Trials*

Diagnosis Studied	Date Of Use	Recipient Age** (yrs)	Time Stored** (months)	Donor Relationship	Cell Count ($x10^8$)
Cerebral Palsy	05/09	4	52	Self	7.57
Cerebral Palsy	04/09	8 months	8	Self	7.78
Cerebral Palsy	04/09	3	34	Self	2.48
Cerebral Palsy	04/09	4	33	Self	9.15
Cerebral Palsy	03/09	5	58	Self	5.92
Cerebral Palsy	03/09	8	93	Self	6.20
Cerebral Palsy	03/09	2	23	Self	5.18
Cerebral Palsy	02/09	1	13	Self	12.71
Cerebral Palsy	02/09	7	79	Self	5.20
Cerebral Palsy	02/09	9	107	Self	12.20
Cerebral Palsy	02/09	7	81	Self	15.40
Cerebral Palsy	02/09	4	47	Self	2.09
Cerebral Palsy	01/09	6	71	Self	10.10
Cerebral Palsy	01/09	4	44	Self	5.00
Cerebral Palsy	01/09	3	38	Self	8.83
Cerebral Palsy	12/08	2	27	Self	3.45
Cerebral Palsy	12/08	4	46	Self	2.95
Cerebral Palsy	12/08	3	40	Self	5.42
Cerebral Palsy	11/08	4	44	Self	3.07
Cerebral Palsy	09/08	1	16	Self	6.58
Cerebral Palsy	09/08	1	16	Self	3.48
Type 1 Diabetes	08/08	5	64	Self	5.16
Cerebral Palsy	08/08	6	73	Self	8.38
Cerebral Palsy	07/08	8 months	8	Self	5.81
Cerebral Palsy	07/08	2	21	Self	2.02
Cerebral Palsy	07/08	2	23	Self	9.70
Traumatic Brain Injury	06/08	4	44	Self	2.96
Traumatic Brain Injury	06/08	4	44	Self	7.57
Type 1 Diabetes	03/07	10	124	Self	6.10
Dysgenesis of the Corpus Callosum	03/07	1	17	Self	13.97

*Banking cord blood does not guarantee that treatment will work and only a doctor can determine when it can be used. Cord tissue stem cells are not approved for use in treatment, but research is ongoing.

**The recipient age and time stored have been rounded to the nearest whole number.

***Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases.

FACILITIES - *ViaCord has released units to over 60 institutions*

All Children's Hospital, St. Petersburg, FL	Indiana University Hospital, Indianapolis, IN	Texas Transplant Institute, San Antonio, TX
Children's Healthcare of Atlanta, GA	Kapi'olani Medical Center for Women & Children, Honolulu, HI	The Johns Hopkins Hospital, Baltimore, MD
Children's Hospital & Research Center, Oakland, CA	Lucile Packard Children's Hospital at Stanford, Palo Alto, CA	The University of Chicago Medical Center, Chicago, IL
Children's Hospital of Alabama, Birmingham, AL	Maria Fareri Children's Hospital, Valhalla, NY	UC Davis Medical Center, Sacramento, CA
Children's Hospital of Orange County, Orange, CA	MD Anderson Cancer Center, Houston, TX	UCLA, Los Angeles, CA
Children's Hospital of Philadelphia, Philadelphia, PA	Medical University of South Carolina, Charleston, SC	UCSF Medical Center, San Francisco, CA
Children's Hospital of Pittsburgh, Pittsburgh, PA	Memorial Sloan-Kettering Cancer Center, New York, NY	University Medical Center, Tucson, AZ
Children's Hospital of Wisconsin, Milwaukee, WI	Miami Children's Hospital, Miami, FL	University General Hospital, Houston, TX
Children's Hospital, Denver, CO	Moffitt Cancer Center, Tampa, FL	University of Erlangen, Erlangen, Germany
Children's Medical Center, Dallas, TX	Mount Sinai Medical Center, New York, NY	University of Louisville, Louisville, KY
Children's Memorial Hospital, Chicago, IL	Nationwide Children's Hospital, Columbus, OH	University of Miami, Miami, FL
Children's Mercy Hospital, Kansas City, KS	Nemours Children's Clinic, Jacksonville, FL	University of Michigan, Ann Arbor, MI
Children's National Medical Center, Washington, D.C.	New York - Presbyterian Hospital, New York, NY	University of Minnesota Amplatz Medical Center, Minneapolis, MN
Cincinnati Children's Hospital Medical Center, Cincinnati, OH	New York Medical College, Valhalla, NY	University of Minnesota, Minneapolis, MN
City of Hope, Duarte, CA	Oregon Health & Science University, Portland, OR	University of Mississippi, Jackson, MS
Cohen Children's Medical Center of New York	Penn State Hershey Medical Center, Hershey, PA	University of Nebraska, Omaha, NE
Columbia University, New York, NY	Primary Children's Medical Center, Salt Lake City, UT	University of North Carolina, Chapel Hill, NC
Columbus Children's Hospital, Columbus, OH	Riley Hospital for Children, Indianapolis, IN	University of Oklahoma, Oklahoma City, OK
Cook Children's Medical Center, Fort Worth, TX	Rush University, Chicago, IL	University of Rochester, Rochester, NY
Dana-Farber Cancer Institute, Boston, MA	Schneider Children's Hospital, New Hyde Park, NY	Vanderbilt University Medical Center, Nashville, TN
Duke University, Durham, NC	Shands University of Florida, Gainesville, FL	Virginia Commonwealth University, Richmond, VA
Fred Hutchinson Cancer Research Center, Seattle, WA	St. Jude Children's Research Hospital, Memphis, TN	
Hackensack University Medical Center, Hackensack, NJ	Texas Children's Hospital, Houston, TX	

WANT TO LEARN MORE ABOUT EMERGING RESEARCH AND POTENTIAL NEW USES FOR CORD BLOOD? TALK TO A VIACORD REPRESENTATIVE OR VISIT US ONLINE.

www.viacord.com | 866-835-0968

For more details and references visit www.viacord.com/references.

ViaCord has released 325 units for transplant or infusion.[1]